The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

References

• FriedmanDSO’ColmainBJMuñosTfor the Eye Diseases Prevalence Research GroupPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol200412256457215078675
   PubMed Web of Science ®Google Scholar
• RogersSMcIntoshRLCheungNfor the International Eye Disease ConsortiumThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology2010117231331920022117
   PubMed Web of Science ®Google Scholar
• BlumenkranzMSNew therapy for central retinal vein occlusion: are intravitreal steroids a possible answer?Arch Ophthalmol200512325926115710826
   PubMedGoogle Scholar
• KempenJHO’ColmainLeskeMCfor the Eye Diseases Prevalence Research GroupThe prevalence of diabetic retinopathy among adults in the United StatesArch Ophthalmol200412255256315078674
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med2003359542743412890841
   PubMed Web of Science ®Google Scholar
• PouesselDCulineSHigh frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptorEur Urol200853237638117825982
   PubMed Web of Science ®Google Scholar
• BerrySRVan CutsemEKretzschmarAFinal efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEATJ Clin Oncol200826Suppl 15 abstract 4025
   Google Scholar
• IzzedineHEderhySGoldwasserFManagement of hypertension in angiogenesis inhibitor-treated patientsAnn Oncol20092080781519150949
   PubMed Web of Science ®Google Scholar
• ZhuXWuSDahutWLParikhCRRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor; systematic review and meta-analysisAm J Kidney Dis200749218619317261421
   PubMed Web of Science ®Google Scholar
• ShahMAIlsonDKelsenDPThromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapyJ Clin Oncol200523112574257615795413
   PubMed Web of Science ®Google Scholar
• GressettSMShahSRIntricacies of bevacizumab-induced toxicities and their managementAnn Pharmacother200943349050119261963
   PubMed Web of Science ®Google Scholar
• ChoYJSeptimiuDMColtHGBronchoscopy for bevacizumab-related hemoptysisLung Cancer20075646546817368626
   PubMed Web of Science ®Google Scholar
• LordickFNeinitzHThelsenJSendlerASarbiaMIncreased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three casesInt J Radiat Oncol Biol Phys20066451295129816503384
   PubMed Web of Science ®Google Scholar
• TotlibVKhaledSLapkoIMarNSaifMWSkin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to responseAnticancer Drugs200617101227122917075324
   PubMed Web of Science ®Google Scholar
• GordonCRRojavinYPatelMA review on bevacizumab and surgical wound healing: an important warning to all surgeonsAnn Plast Surg200962670770919461291
   PubMed Web of Science ®Google Scholar
• ZawackiWJWalkerTGDeVasherEWound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapyJ Vasc Interv Radiol200920562462719328717
   PubMed Web of Science ®Google Scholar
• ThorntonADRavnPWinsletMChesterKAngiogenesis inhibition with bevacizumab and the surgical management of colorectal cancerBr J Surg200693121456146317115389
   PubMed Web of Science ®Google Scholar
• ScappaticciFAFehrenbacherLCartwrightTSurgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumabJ Surg Oncol200591317318016118771
   PubMed Web of Science ®Google Scholar
• AllegraCJYothersGO’ConnellMJInitial Safety Report of NSABP C-08: A randomized phase III study of modified FOL-FOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer (BEAT)J Clinic Oncol20092733853390
   PubMed Web of Science ®Google Scholar
• BoseDMeric-BernstamFHofstetterWReardonDAFlahertyKTEllisLMVascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient careLancet Oncol201011437338220171141
   PubMed Web of Science ®Google Scholar
• EllisLMCurleySAGrotheyASurgical resection after downsizing of colorectal liver metastasis in the era of bevacizumabJ Clinic Oncol20052348534855
   PubMed Web of Science ®Google Scholar
• SugrueMMPurdieDMFengSSerious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS)Proc Am Soc Clin Oncol200826Suppl 15 abstract 4105
   Google Scholar
• MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJfor the CATT Research GroupRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• CullenKAHallMJGolosinskiyAAmbulatory surgery in the United States, 2006Natl Health Stat Report20091112519294964
   PubMedGoogle Scholar
• AbramovYGoldenBSullivanMHistologic characterization of vaginal vs abdominal surgical wound healing in a rabbit modelWound Repairs Regen20071518086
   PubMed Web of Science ®Google Scholar
• ShroutPEFleissJLIntraclass correlations: Uses in assessing rater reliabilityPsychol Bull19798642042818839484
   PubMed Web of Science ®Google Scholar
• HuntTWound Healing and Wound Infection: Theory and Surgical PracticeNew YorkAppleton-Century-Crofts1980
   Google Scholar
• HowdieshellTRRiegnerCGuptaVCallawayDSathyanarayanaMcNeilPLNormoxic wound fluid contains high levels of vascular endothelial growth factorAnn Surg19982287077159833810
   PubMed Web of Science ®Google Scholar
• BrownLFVan De WaterLHarveryVSDvorakHFFibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stromaAm J Pathol19881304554653279791
   PubMed Web of Science ®Google Scholar
• BreuingKErikssonELivPMillerDRHealing of partial thickness porcine skin wounds in a liquid environmentJ Surg Res199252501548868
   PubMed Web of Science ®Google Scholar
• HowdieshellTRCallawayDWebbWLAntibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formationJ Surg Res20019617318211266270
   PubMed Web of Science ®Google Scholar
• RichRMRosenfeldPJPulafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina20062649551116770255
   PubMed Web of Science ®Google Scholar
• MichelsSRosenfeldPJPuliafitoCAMarcusENVenkatramanASSystemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical studyOphthalmology200511261035104715936441
   PubMed Web of Science ®Google Scholar
• CsakyKDoDVSafety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapiesAm J Ophthalmol2009148564765619712924
   PubMed Web of Science ®Google Scholar
• ChakravarthyUAdamisAPCunninghamETJrGoldbaumMGuyerDRVEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupYear 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degenerationOphthalmology20061131508152116828500
   PubMed Web of Science ®Google Scholar
• HeldinCHWestermarkBMechanism of action and in-vivo role of platelet-derived growth factorPhysiol Rev1999791283131610508235
   PubMed Web of Science ®Google Scholar
• LiekensSDe ClercqENeytsJAngiogenesis: Regulators and clinical applicationsBiochem Pharmacol20016125327011172729
   PubMed Web of Science ®Google Scholar
• SingerAJClarkRACutaneous wound healingN Engl J Med199934173874610471461
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of ranibizumab after a single intravitreal administrationInvest Ophthalmol Vis Sci20054672673315671306
   PubMed Web of Science ®Google Scholar
• MiyakeTSawadaOKakinokiMPharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyesInvest Ophthalmol Vis Sci2010511606160819875666
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSSinghRJPharmacokinetics of intravitreal bevacizumab (Avastin)Ophthalmology2007114585585917467524
   PubMed Web of Science ®Google Scholar
• Macugen (pegaptanib sodium injection) product informationRX ListThe Internet Drug List Available at: http://www.rxlist.com/macugen-drug.htmAccessed February 11, 2009
   Google Scholar
• GradSErtelWKeelMInfangerMVonderschmittDJMalyFEStrongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burnClin Chem Lab Med19983663793839711425
   PubMed Web of Science ®Google Scholar
• LarssonASkoldenbergEEricsonHSerum and plasma levels of FGF-2 and VEGF in healthy blood donorsAngiogenesis2002410711012549867
   PubMedGoogle Scholar
• DouzinasEBetrosianALivaditiOHypoxemic resuscitation after hemorrhagic shock is accompanied by reduced serum levels of angiopoietin-2Cytokine2009472828419540132
   PubMed Web of Science ®Google Scholar
• LinYSNguyenCMedozaJLPreclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factorJ Pharmacol Exp Ther19992993713789862791
   PubMed Web of Science ®Google Scholar
• WatkinsRHD’AngioCTRyanRMPatelAManiscalcoWMDifferential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injuryAm J Physiol19992765 Pt 1858867
   Google Scholar